{"id":"kineret-anakinra","safety":{"commonSideEffects":[{"rate":"71","effect":"Injection site reactions"},{"rate":"12","effect":"Headache"},{"rate":"8","effect":"Nausea"},{"rate":"7","effect":"Diarrhea"},{"rate":"5","effect":"Infections"}]},"_chembl":{"chemblId":"CHEMBL1201570","moleculeType":"Protein"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Anakinra competitively inhibits the binding of interleukin-1 (IL-1) to the IL-1 type I receptor, preventing the pro-inflammatory effects of IL-1. By blocking this key inflammatory cytokine, it reduces the production of other inflammatory mediators and decreases immune cell activation, thereby suppressing the inflammatory cascade in autoimmune and autoinflammatory conditions.","oneSentence":"Anakinra is a recombinant interleukin-1 receptor antagonist that blocks IL-1 signaling to reduce inflammation.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:51:08.962Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Rheumatoid arthritis"},{"name":"Neonatal-onset multisystem inflammatory disease (NOMID)"},{"name":"Deficiency of interleukin-1 receptor antagonist (DIRA)"}]},"trialDetails":[{"nctId":"NCT06710197","phase":"PHASE2","title":"IL-1 Inhibition in Early TNBC","status":"WITHDRAWN","sponsor":"University Health Network, Toronto","startDate":"2025-03-05","conditions":"Early Stage Triple Negative ER Low Breast Cancer","enrollment":""},{"nctId":"NCT05174507","phase":"PHASE2","title":"Empagliflozin and Anakinra for the Treatment of Postprandial Hypoglycemia in Patients With Prediabetes","status":"WITHDRAWN","sponsor":"University Hospital, Basel, Switzerland","startDate":"2022-06-24","conditions":"Postprandial Hypoglycemia","enrollment":""},{"nctId":"NCT07371689","phase":"PHASE3","title":"ANAKINRA IN THE TREATMENT OF PEDIATRIC ACUTE MYOCARDITIS","status":"NOT_YET_RECRUITING","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2026-02","conditions":"PEDIATRIC ACUTE MYOCARDITIS","enrollment":110},{"nctId":"NCT07254000","phase":"PHASE2","title":"Anakinra Pilot 2 - A Study to Optimise Dose and Route of Administration of Anakinra in Preterm Infants","status":"RECRUITING","sponsor":"Monash Medical Centre","startDate":"2025-06-27","conditions":"Premature Infants, Very Premature Infants, Inflammation","enrollment":24},{"nctId":"NCT04150913","phase":"PHASE2","title":"A Phase 2 Trial of Anakinra for the Prevention of CAR-T Cell Mediated Neurotoxicity","status":"COMPLETED","sponsor":"Marcela V. Maus, M.D.,Ph.D.","startDate":"2020-10-01","conditions":"Non Hodgkin Lymphoma, Refractory Non-Hodgkin Lymphoma, Relapsed Non Hodgkin Lymphoma","enrollment":15},{"nctId":"NCT06703216","phase":"PHASE1, PHASE2","title":"Pre-emptive Anakinra for Cytokine Event Reduction","status":"NOT_YET_RECRUITING","sponsor":"Ann & Robert H Lurie Children's Hospital of Chicago","startDate":"2025-08","conditions":"B-Acute Lymphoblastic Leukemia, CAR-T Cell Therapy, Cytokine Release Syndrome","enrollment":24},{"nctId":"NCT04341584","phase":"PHASE2","title":"CORIMUNO-ANA: Trial Evaluating Efficacy Of Anakinra In Patients With Covid-19 Infection","status":"COMPLETED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2020-04-08","conditions":"Corona Virus Infection","enrollment":161},{"nctId":"NCT04227769","phase":"PHASE2","title":"IL-1-receptor Antagonist During Cephalic Phase of Insulin Secretion in Health and Type 2 Diabetes","status":"TERMINATED","sponsor":"University Hospital, Basel, Switzerland","startDate":"2020-01-13","conditions":"Diabetes Mellitus Type 2 in Obese, Inflammation, Metabolic Disease","enrollment":18},{"nctId":"NCT05854251","phase":"PHASE2","title":"Hyperinsulinemia in Prediabetes Mediated by Interleukin-1β","status":"COMPLETED","sponsor":"University Hospital, Basel, Switzerland","startDate":"2023-06-15","conditions":"Hyperinsulinemia, PreDiabetes","enrollment":20},{"nctId":"NCT03932344","phase":"","title":"Long-term Safety Study of Kineret® in Patients With Systemic Juvenile Idiopathic Arthritis (SJIA)","status":"COMPLETED","sponsor":"Swedish Orphan Biovitrum","startDate":"2019-04-10","conditions":"Still Disease, Juvenile Onset","enrollment":306},{"nctId":"NCT04330638","phase":"PHASE3","title":"Treatment of COVID-19 Patients With Anti-interleukin Drugs","status":"COMPLETED","sponsor":"University Hospital, Ghent","startDate":"2020-04-03","conditions":"COVID-19","enrollment":342},{"nctId":"NCT03141983","phase":"PHASE2","title":"Anti-Cytokine Therapy for Hemodialysis InflammatION","status":"COMPLETED","sponsor":"University of Pennsylvania","startDate":"2017-12-15","conditions":"End-Stage Renal Disease","enrollment":80},{"nctId":"NCT04643678","phase":"PHASE2, PHASE3","title":"Anakinra in the Management of COVID-19 Infection","status":"COMPLETED","sponsor":"Hamad Medical Corporation","startDate":"2020-10-30","conditions":"Covid19, Pneumonia, Cytokine Release Syndrome","enrollment":80},{"nctId":"NCT03737344","phase":"PHASE2","title":"BLOC-ICH: Interleukin-1 Receptor Antagonist in Intracerebral Haemorrhage","status":"COMPLETED","sponsor":"Adrian Parry-Jones","startDate":"2019-05-17","conditions":"Intracerebral Haemorrhage","enrollment":25},{"nctId":"NCT03265132","phase":"PHASE3","title":"A Study to Evaluate Efficacy and Safety of Anakinra in the Treatment of Still's Disease (SJIA and AOSD)","status":"TERMINATED","sponsor":"Swedish Orphan Biovitrum","startDate":"2017-09-26","conditions":"Still's Disease, Adult-Onset, Still's Disease, Juvenile-Onset","enrollment":13},{"nctId":"NCT02550327","phase":"EARLY_PHASE1","title":"Gemcitabine, Nab-Paclitaxel, Cisplatin and Anakinra Treatment on Patients With Pancreatic Cancer","status":"COMPLETED","sponsor":"Baylor Research Institute","startDate":"2016-01","conditions":"Pancreatic Adenocarcinoma","enrollment":20},{"nctId":"NCT04462757","phase":"PHASE2","title":"SCIL-1Ra in COVID-19 Feasibility & PK/PD","status":"TERMINATED","sponsor":"University of Manchester","startDate":"2020-05-28","conditions":"COVID-19","enrollment":5},{"nctId":"NCT04412291","phase":"PHASE2","title":"A Study in Patients With COVID-19 and Respiratory Distress Not Requiring Mechanical Ventilation, to Compare Standard-of-care With Anakinra and Tocilizumab Treatment The Immunomodulation-CoV Assessment (ImmCoVA) Study","status":"UNKNOWN","sponsor":"Karolinska University Hospital","startDate":"2020-06-11","conditions":"Covid-19","enrollment":120},{"nctId":"NCT03578497","phase":"PHASE2","title":"Effects of Interleukin-1 Receptor Antagonism on Hyperandrogenemia in Women With Polycystic Ovary Syndrome","status":"COMPLETED","sponsor":"University Hospital, Basel, Switzerland","startDate":"2018-08-31","conditions":"Polycystic Ovary Syndrome","enrollment":18},{"nctId":"NCT03288584","phase":"","title":"Effects of Interleukin-6 Inhibition on Vascular, Endothelial and Left Ventricular Function in Rheumatoid Arthritis","status":"UNKNOWN","sponsor":"University of Athens","startDate":"2017-10-27","conditions":"Rheumatoid Arthritis, Inflammation","enrollment":60},{"nctId":"NCT03850080","phase":"PHASE2, PHASE3","title":"Autologous Conditioned Serum: Functional and Clinical Results","status":"COMPLETED","sponsor":"Ospedale San Raffaele","startDate":"2017-10-06","conditions":"Knee Osteoarthritis, Osteoarthritis, Knee, Cartilage Degeneration","enrollment":15},{"nctId":"NCT02672592","phase":"PHASE3","title":"Effects of Interleukin-1 Beta on Low Testosterone Levels in Men With Obesity and Metabolic Syndrome","status":"COMPLETED","sponsor":"University Hospital, Basel, Switzerland","startDate":"2016-01","conditions":"Hypogonadism, Metabolic Syndrome X, Obesity","enrollment":70},{"nctId":"NCT00111410","phase":"PHASE4","title":"Evaluating the Effect of Anakinra (r-metHuIL-1ra) on Vaccine AntibodyResponse in Subjects With Rheumatoid Arthritis (RA)","status":"COMPLETED","sponsor":"Amgen","startDate":"","conditions":"Rheumatoid Arthritis","enrollment":""},{"nctId":"NCT02175056","phase":"PHASE1","title":"A Dose-Block Randomized, Placebo Controlled (Double-blind), Active Controlled(Open-label), Dose-escalation Study","status":"COMPLETED","sponsor":"Handok Inc.","startDate":"2014-05","conditions":"Healthy Volunteers","enrollment":58},{"nctId":"NCT01566201","phase":"NA","title":"Effects of Interleukin-1 Inhibition on Vascular and Left Ventricular Function in Rheumatoid Arthritis Patients With Coronary Artery Disease","status":"COMPLETED","sponsor":"University of Athens","startDate":"2011-03","conditions":"Rheumatoid Arthritis, Coronary Artery Disease, Inflammation","enrollment":80},{"nctId":"NCT00711503","phase":"PHASE2, PHASE3","title":"Anti-Interleukin-1 in Diabetes Action","status":"COMPLETED","sponsor":"Steno Diabetes Center Copenhagen","startDate":"2009-01","conditions":"Type 1 Diabetes","enrollment":69},{"nctId":"NCT00121043","phase":"PHASE4","title":"Evaluating Kineret® (Anakinra) in Rheumatoid Arthritis (RA) Subjects Using aSelf-Reported Questionnaire","status":"COMPLETED","sponsor":"Amgen","startDate":"","conditions":"Rheumatoid Arthritis","enrollment":""},{"nctId":"NCT00121056","phase":"","title":"REKinDLE: Registry With Enbrel® or Kineret® in a Database Using Longitudinal Evaluations","status":"COMPLETED","sponsor":"Amgen","startDate":"2002-09","conditions":"Rheumatoid Arthritis","enrollment":""},{"nctId":"NCT00117091","phase":"PHASE3","title":"Anakinra (Kineret®) in Combination With Disease Modifying Anti-Rheumatic Drugs (DMARDS) in Subjects With Active Rheumatoid Arthritis (RA)","status":"COMPLETED","sponsor":"Amgen","startDate":"","conditions":"Rheumatoid Arthritis","enrollment":""}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Kineret® (Anakinra)","genericName":"Kineret® (Anakinra)","companyName":"Amgen","companyId":"amgen","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Anakinra is a recombinant interleukin-1 receptor antagonist that blocks IL-1 signaling to reduce inflammation. Used for Rheumatoid arthritis, Neonatal-onset multisystem inflammatory disease (NOMID), Deficiency of interleukin-1 receptor antagonist (DIRA).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}